Publications by authors named "R Chis"
Introduction: Chronic calcific pancreatitis (CCP) is a debilitating inflammatory condition characterized by the accumulation of calcific deposits in the pancreatic tissue, leading to chronic abdominal pain and functional insufficiencies. This study aims to systematically review and meta-analyse comparative studies assessing the efficacy of endotherapy versus surgery in managing CCP-related pain.
Methods: MEDLINE, EMBASE, and Cochrane library (CENTRAL and CDSR), from inception to October 2023, were searched.
Article Synopsis
- Monosodium glutamate (MSG) is a flavor enhancer with both controversial and beneficial effects, particularly regarding its impact on glutamic acid metabolism in terms of homeostasis.* -
- A study on aged Wistar rats examined the health effects of varying MSG doses over 90 days by analyzing blood markers and conducting histopathological evaluations of organs.* -
- Results indicated that the positive aspects of glutamic acid metabolism were more apparent than the negative effects, suggesting a possible protective mechanism against oxidative stress in older subjects with MSG consumption.*
The 2023 Impact of Inflammatory Bowel Disease in Canada: Cancer and IBD.
J Can Assoc Gastroenterol
September 2023
Cancer is a major cause of morbidity and mortality among people with inflammatory bowel disease (IBD). Intestinal cancers may arise as a complication of IBD itself, while extra-intestinal cancers may arise due to some of the immunosuppressive therapies used to treat IBD. Colorectal cancer (CRC) and small bowel cancer risks remain elevated among persons with IBD as compared to age-and sex-matched members of the general population, and the lifetime risk of these cancers is strongly correlated to cumulative intestinal inflammatory burden.
View Article and Find Full Text PDFThe 2023 Impact of Inflammatory Bowel Disease in Canada: Treatment Landscape.
J Can Assoc Gastroenterol
September 2023
The therapeutic landscape for inflammatory bowel disease (IBD) has changed considerably over the past two decades, owing to the development and widespread penetration of targeted therapies, including biologics and small molecules. While some conventional treatments continue to have an important role in the management of IBD, treatment of IBD is increasingly moving towards targeted therapies given their greater efficacy and safety in comparison to conventional agents. Early introduction of these therapies-particularly in persons with Crohn's disease-combining targeted therapies with traditional anti-metabolite immunomodulators and targeting objective markers of disease activity (in addition to symptoms), have been shown to improve health outcomes and will be increasingly adopted over time.
View Article and Find Full Text PDF